Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
about
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancerPegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancerPhase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsManagement of relapsed ovarian cancer: a reviewThe Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological CancerChemotherapy of ovarian cancer in elderly patientsSelecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patientsPegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trialsOvarian cancer standard of care: are there real alternatives?Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Advanced ovarian cancer: what should be the standard of care?Integrated genomic analyses of ovarian carcinomaBevacizumab in ovarian cancer: A critical review of phase III studiesNew perspectives on targeted therapy in ovarian cancerMulti-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.High throughput interrogation of somatic mutations in high grade serous cancer of the ovaryA phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studyThe use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisA putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patientsImproving cancer outcomes through international collaboration in academic cancer treatment trials.Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells.Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancerMolecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer
P2860
Q24201282-9AF68D35-9BAF-41B0-BA3D-4B2578A6C5A0Q24202975-C368DE67-1EAB-4095-8DC8-B7C1061C02EDQ24633820-DFCE8482-B609-401D-9D4B-A1468C48ACD0Q26741755-6A13562C-2DA9-451E-A61F-C30D2ADD8791Q26770278-16AA74BA-305F-4A90-8801-A304DA7990CBQ26771397-1BB3A3B9-F2CD-4080-B3F6-F3C79FF8AF1BQ26771731-C47B156B-2D3F-4061-AA37-1105642F215DQ26858830-7478AABC-72B6-4A8C-9F74-DF233F628EACQ26862249-66418AC5-D930-41B4-BAF5-61F03EB6FE1CQ27851688-4868EA15-9A4B-4DFA-B71A-6EB5557CF270Q27852053-C09DF3C7-0C3B-43A5-BE9A-DDD095707799Q27860518-54884059-6E55-4795-87C4-3586FE1B882EQ28076188-6FC14080-442A-40E4-9A7A-CBDEF26B1BDAQ28082524-EA67BB6F-8DFA-44E8-BE10-96695042D45BQ28480595-1C750CFF-FF01-4DC5-A051-4B31FA2F8A90Q28539509-A2A2D32A-BAFF-4BF7-B920-014DBB567CACQ28740553-CBA8BC72-98A1-4684-84B2-D759ADA9EE29Q30299971-52BAEAB9-8E80-48D5-B969-957F89468ACFQ30356222-0CE0D6C3-F82A-4431-B27B-04E2337C9792Q30360249-99C26A35-14AB-4597-AFB0-F28F9E78A6B5Q30361070-A394AEB9-52A1-4A80-9183-05EBFBB38663Q30405874-2780B5CE-4463-4BDC-880B-E2CB377E3E78Q30419554-E88887F6-645C-46DF-BBF9-A691332BDBCEQ30453014-19D0A97C-8787-4748-B17C-89B4154C8EC0Q30540674-050F5C15-6215-4604-9404-E9B2609B897CQ31010361-EA948F32-31A7-4B39-9E79-C529830FA1EAQ31143363-6460ACA5-1CCC-40F8-A65C-6DFE3D2B7538Q33354953-E8C27322-BE66-4C96-A23D-E65BFD711041Q33393879-7FFDAAFA-CC64-446E-BA17-1E74B967B17EQ33407574-CE9CF6CD-E7DF-4C24-9892-6CE12B0D646EQ33409319-2E3AEF43-310B-4FB2-BB47-E43BAAFDE3C5Q33553922-473096A4-60D0-4D87-9C35-FCC8BB755DC8Q33561197-456DD4CE-B98C-4EFA-A23B-6AB0FB1BDA64Q33718820-E974B749-0DB7-42A3-BBBD-436232795F0EQ33723639-E156562F-B8D3-494A-8109-A287B60BA8DAQ33735170-4C4DA6BE-A471-4979-8206-DED5A1198C39Q33750813-60072EE7-4B36-43C2-8B4D-21F12FD2D65CQ33768759-9A8E146D-1D02-4210-BD84-1529C5EA50D0Q33774527-96B33D15-1264-4B66-B99A-187CAD366EA1Q33774648-FA167817-CD1D-495B-AA03-F7205AFCEDB5
P2860
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@ast
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@en
type
label
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@ast
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@en
prefLabel
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@ast
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@en
P2093
P2860
P356
P1476
Evaluation of new platinum-bas ...... Gynecologic Cancer Intergroup.
@en
P2093
Ann Marie Swart
Chrisann Accario-Winslow
David G Mutch
David S Alberts
Edward L Trimble
Jeffrey M Fowler
Koen De Geest
Lawrence M Roth
Mark F Brady
Michael A Bookman
P2860
P304
P356
10.1200/JCO.2008.19.1684
P407
P577
2009-02-17T00:00:00Z